Blood brain barrier receptor antibodies and methods of use
AssigneeGenentech, Inc.
InventorsChristine Tan, Ryan J. Watts, Joy Yu Zuchero, Xiaocheng Chen, Mark S. Dennis
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies that bind to receptors expressed on the blood brain barrier and methods of using the same.
Claims122
A method of transporting an agent across the blood-brain barrier, wherein the method comprises exposing the blood-brain barrier to an antibody which (i) binds to a blood-brain barrier receptor (BBB-R);
- and (ii) is coupled to the agent;
- wherein:
- the antibody, upon binding to the BBB-R, transports the agent coupled thereto across the blood-brain barrier;
- and
- the BBB-R is a member selected from the group consisting of CD98 heavy chain (CD98hc), basigin, and Glucose Transporter Type 1 (Glut1).
A method of treating a neurological disease or disorder in a mammal, wherein the method comprises administering to the mammal an antibody which (i) binds to a BBB-R selected from the group consisting of CD98hc, basigin, and Glut1;
- and (ii) is coupled to a therapeutic agent which is effective for treating the neurological disease or disorder.
An isolated antibody that binds to basigin, wherein the antibody comprises:
- (a) one or more of the heavy chain complementarity determining region (CDR) 1, 2, and 3 sequences comprising the amino acid sequences of SEQ ID NOs:
- 6, 7, and 8, respectively;
- and/or
- (b) one or more of the light chain CDR 1, 2, and 3 sequences comprising the amino acid sequences of SEQ ID NOs:
- 3, 4, and 5, respectively.
An isolated antibody that binds to basigin, wherein the antibody comprises:
- (a) one or more of heavy chain CDR 1, 2, and 3 sequences comprising the amino acid sequences of SEQ ID NOs:
- 22, 23, and 24, respectively;
- and/or
- (b) one or more of light chain CDR 1, 2, and 3 sequences comprising the amino acid sequences of SEQ ID NOs:
- 19, 20, and 21, respectively.
An isolated antibody that binds to basigin, wherein the antibody comprises:
- (a) one or more of the heavy chain CDR 1, 2, and 3 sequences comprising the amino acid sequences of SEQ ID NOs:
- 38, 39, and 40, respectively;
- and/or
- (b) one or more of the light chain CDR 1, 2, and 3 sequences comprising the amino acid sequences of SEQ ID NOs:
- 35, 36, and 37, respectively.
An isolated antibody that binds to basigin, wherein the antibody comprises:
- (a) one or more of the heavy chain CDR 1, 2, and 3 sequences comprising the amino acid sequences of SEQ ID NOs:
- 54, 55, and 56, respectively;
- and/or
- (b) one or more of the light chain CDR 1, 2, and 3 sequences comprising the amino acid sequences of SEQ ID NOs:
- 51, 52, and 53, respectively.
An isolated antibody that binds to basigin, wherein the antibody comprises:
- (a) one or more of the heavy chain CDR 1, 2, and 3 sequences comprising the amino acid sequences of SEQ ID NOs:
- 70, 71, and 72, respectively;
- and/or
- (b) one or more of the light chain CDR 1, 2, and 3 sequences comprising the amino acid sequences of SEQ ID NOs:
- 67, 68, and 69, respectively.
An isolated antibody that binds to Glut1, wherein the antibody comprises:
- (a) one or more of the heavy chain CDR 1, 2, and 3 sequences comprising the amino acid sequences of SEQ ID NOs:
- 86, 87, and 88, respectively;
- and/or
- (b) one or more of the light chain CDR 1, 2, and 3 sequences comprising the amino acid sequences of SEQ ID NOs:
- 83, 84, and 85, respectively.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.